Answers are grounded in this paper and cite their sources.
Rhabdomyosarcoma is the most common soft-tissue sarcoma in children in the United States with an incidence of 4.5 per million, which translates into approximately 350 new diagnoses per year. The use of risk-based multimodal therapies developed by cooperative groups has been largely responsible for improving the 5-year survival rates for this disease, which now exceed 70%. Despite marked improvements in the outcomes of most children with rhabdomyosarcoma, survival rates for patients with metastatic disease and select patients with intermediate-risk disease, such as those with unresectable stage 2/3 tumors, have not significantly improved over the past 30 years. The Children’s Oncology Group Soft Tissue Sarcoma Committee (COG-STS) has used vincristine, actinomycin, and cyclophosphamide (VAC) as the main backbone for treating rhabdomyosarcoma. To improve the survival of patients with intermediate-risk disease, the COG-STS conducted a series of clinical trials in which doses of active agents were intensified or novel agents such as camptothecins were incorporated. Promising activity was found in phase 2 window trials of patients with metastatic rhabdomyosarcomas. For example, in a prospective single-arm trial of 115 patients with intermediate-risk rhabdomyosarcoma, dose escalation of cyclophosphamide to 4.5 g/m did not result in improved outcomes and was associated with significant gastrointestinal toxicity. In the prospective randomized trial D9803, 516 patients with intermediate-risk rhabdomyosarcoma were randomly assigned to receive VAC chemotherapy with a cyclophosphamide dose of 2.2 g/m or VAC alternating with vincristine, cyclophosphamide, and topotecan (VTC; Table 1). The estimated 4-year failure-free survival and overall survival rates were similar for the 2 arms. In the most recent trial ARST0531, which is the subject of this report, 448 patients with intermediate-risk rhabdomyosarcoma were randomized to receive VAC chemotherapy or VAC alternating with vincristine and irinotecan (VI). The 4-year event-free survival and overall survival rates were similar for both arms, but the VAC/VI arm had fewer hematologic toxicities and more gastrointestinal toxicities than the VAC arm. On the basis of these results, the COG-STS adopted VAC/VI as the new backbone for therapy for patients with intermediate-risk disease in the ongoing study ARST1431. In a study published in Cancer, Casey and investigators of the COG-STS report increased local failure rates in patients with intermediate-risk rhabdomyosarcoma enrolled in ARST0531. Eligibility criteria for this trial included a diagnosis of nonmetastatic alveolar rhabdomyosarcoma or incompletely resected embryonal rhabdomyosarcoma arising at unfavorable sites (stage 2/3, group III). Chemotherapy consisted of VAC at a dose of 1.2 g/m or VAC alternating with VI. Local control started at week 4, and radiation therapy (RT) doses were tailored to the volume of the residual tumor. Patients with node-negative group I/II alveolar tumors received 36 Gy, whereas those with nodal disease received 41.4 Gy. Patients with gross residual disease (group III) received a total cumulative dose of 50.4 Gy to a response-adjusted volume after chemotherapy. The 2 randomized groups were well balanced with respect to baseline patient characteristics. Group III embryonal tumors were present in 54%, 33% had group III alveolar tumors, and 13% had group I/II alveolar tumors. The most common primary site was the parameningeal region (45%), which was followed by the genitourinary tract (13%) and extremities (13%). The local failure rate for patients with group I/II alveolar tumors was 14.4%, which was similar to the rate of 8.6% reported in the previous COG-STS D9803 trial. In the 369 patients with group III disease, the incidence of local failure at 5 years was 25.4%, with higher local failure rates in patients with embryonal tumors (28.4% vs 20.2%). A tumor size >5 cm was associated with a higher local failure rate (32.3% vs 16.7%). Local failures rates were similar in patients who received VAC (21.3%) or VAC/VI (26.1%), and the modality of RT used,
No takes yet. Share an insight, caveat, or question.
Lucas et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: